Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14575869 | 1.00 | HTR2A (0.46) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL15136221 | 0.98 | HTR2A (0.45) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL15136222 | 0.98 | HTR2A (0.45) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL14575792 | 0.94 | KDM4E (0.46) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL14575794 | 0.94 | KDM4E (0.46) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL14576547 | 0.92 | KDM4E (0.45) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL14576545 | 0.92 | KDM4E (0.45) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL15171151 | 0.84 | LSS (0.40) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL14617850 | 0.82 | HTR2A (0.39) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL30719715 | 0.82 | LSS (0.39) | HTR2AHTR2CHTR2BSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4263542-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-10793576-B2 | Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof | CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190315758-A1 | COMPOUND USED AS BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190144451-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC | 2019-05-16 | — | — | US | disclosed |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015002894-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014078578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2731612-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013102059-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE AND PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2013010136-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | HTR2A 1642/4885HTR2C 1616/4885HTR2B 1052/4885 |
| US-20190315758-A1 | COMPOUND USED AS BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | BTK, SYK, LYN | HTR2A 4489/4885HTR2C 4032/4885HTR2B 3788/4885 |
| US-20190144451-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | HTR2A 1642/4885HTR2C 1616/4885HTR2B 1052/4885 |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | HTR2A 3635/4885HTR2C 2751/4885HTR2B 3099/4885 |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HTR2A 4344/4885HTR2C 4352/4885HTR2B 3802/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | HTR2A 4474/4885HTR2C 3968/4885HTR2B 4154/4885 |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2A 4019/4885HTR2C 3734/4885HTR2B 3298/4885 |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | HTR2A 4363/4885HTR2C 4102/4885HTR2B 3734/4885 |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | HTR2A 4000/4885HTR2C 3942/4885HTR2B 3559/4885 |
| US-10793576-B2 | Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof | BTK, SYK, LYN | HTR2A 4489/4885HTR2C 4032/4885HTR2B 3788/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2A 3909/4885HTR2C 3688/4885HTR2B 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.